Citations

Clear

2960 citation(s) found for "Kim, P".

Comprehensive Genomic Profiling of Sinonasal Carcinomas: Identification of Common Mutations and Potential Targets for Therapy
Bitar, Gabriel , Hsia, Beau , Alshaka, Saif, Kim, Jeeho D. , Levy, Michael L. , Valencia, Bastien A. , Hsia, Beau , Sato, Mariko , Crawford, John Ross , Polster, Sean P. , Patel, Vijay A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 18, 2025 | Volume: 87 | Issue: 03 | Pages: 337-344

10.1055/a-2639-5790 | PMID 42095034 Get It

Abstract Sinonasal cancers are malignant neoplasms arising from the nasal cavity and paranasal sinuses, including squamous cell carcinoma (SCC), adenocarcinoma, and undifferentiated carcinoma. Due to their rarity, comprehensive genomic data remain limited. Treatments include surgery, radiation, and chemotherapy, with ongoing trials investigating agents like cetuximab, cisplatin, and Tazemetostat. We analyzed sinonasal cancer cases from the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database via cBioPortal (v16.1-public, accessed July 22, 2024). Common gene mutations, correlations, and mutual exclusivities were assessed using statistical analyses with false discovery rate correction. Of 2,595 head and neck cancer samples, 122 (4.7%) were sinonasal carcinoma: 70 (57.4%) SCC, 31 (25.4%) undifferentiated carcinoma, and 21 (17.2%) adenocarcinomas. The most frequent mutations were TP53 (tumor protein 53; 40%), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; 14%), KMT2D (lysine methyltransferase 2D; 11%), and CDKN2A (cyclin-dependent kinase inhibitor 2A; 9%). Subtype-specific mutations included IDH2 (isocitrate dehydrogenase; 230%) in undifferentiated carcinoma and FAT1 (15%) in adenocarcinoma. TP53 frequently co-occurred with PRKDC (protein kinase, DNA-activated, catalytic subunit; p = 0.020), while KMT2D co-occurred with PIK3CA (p = 0.018). TP53, PIK3CA, and KMT2D mutations are prevalent in sinonasal carcinoma, highlighting potential targets for therapy. Tazemetostat, targeting KMT2D-related DNA (deoxyribonucleic acid) methylation, and cetuximab, targeting the PIK3CA signaling cascade, may offer therapeutic benefits. Further research on mutation-specific therapies could improve treatment strategies.
Molecular Profiling of Olfactory Neuroblastoma Using the AACR Project GENIE Database
Hsia, Beau , Dongre, Roshan , Erquizi, Aya, Guerra-Navarro, Paula V., Bitar, Gabriel , Alshaka, Saif, Kim, Jeeho D. , Valencia-Sanchez, Bastien A., Levy, Michael L. , Hsia, Beau , Guerra-Navarro, Paula Valeria, Valencia-Sanchez, Bastien A., Brandel, Michael G. , Sato, Mariko , Crawford, John Ross , Patel, Vijay A. , Polster, Sean P.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 18, 2025 | Volume: 87 | Issue: 03 | Pages: 330-336

10.1055/a-2639-5690 | PMID 42095028 Get It

Abstract Olfactory neuroblastoma (ONB) is a rare head and neck cancer arising from the upper nasal cavity, with limited systemic therapeutic options due to a poor understanding of its genomic landscape. This study aims to utilize a patient-level genomic repository to identify potential therapeutic targets and improve disease modeling in ONB. Retrospective genomic analysis. Data analysis was performed using the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database. Patients with confirmed ONB who have undergone targeted sequencing within GENIE. Data were analyzed for recurrent somatic mutations, along with their clinical and demographic correlations, with significance set at p < 0.05. A high prevalence of mutations in TP53 (tumor protein p53) and FRK (fibroblast growth factor receptor kinase) genes was identified. A moderate prevalence of mutations in NOTCH3 (notch receptor 3), SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4), RET (rearranged during transfection), and CTCF (CCCTC-binding factor) was also identified. The mutation patterns differed between pediatric and adult ONB cases. Specific mutations were enriched in metastatic tumors compared with primary tumors. This study provides a genomic profile for ONB, identifying key mutations and potential therapeutic targets. The identification of frequently mutated genes like TP53 and FRK suggests potential targets for novel therapies. The observation that certain genes are mutated in pediatric ONB but not adult ONB (and vice versa), and the presence of specific mutations in metastatic tumors that are absent in primary tumors, offers valuable insights for future precision medicine and the design of targeted therapeutic interventions for these distinct clinical presentations.
Treatment outcomes of successful M1 versus M2 thrombectomy for low-ASPECTS stroke patients
Chen, Huanwen , Colasurdo, Marco , Maier, Ilko , Jabbour, Pascal , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Levitt, Michael R, Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kan, Peter, Jabbour, Pascal , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Altschul, David J , Crosa, Roberto , Colasurdo, Marco , Matsukawa, Hidetoshi , Cunningham, Conor M. , Shaban, Amir , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Matouk, Charles , Park, Min S. , Navía, Pedro , Chen, Huanwen

Mayo Clinic

Interventional Neuroradiology | June 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251343283 | PMID 40530425 Get It

Background The effectiveness of endovascular thrombectomy (EVT) for low Alberta Stroke Program Early CT score (ASPECTS) stroke patients with occlusion of the second segment of the middle cerebral artery (M2) is unclear. Methods This was a multicenter retrospective study. Patients with M1 or M2 occlusions and low ASPECTS (<6) who underwent successful EVT (modified treatment in cerebral ischemia score of 2b or higher) were included. Primary outcome was futile EVT reperfusion (defined as 90-day modified Rankin scale of 5 or 6). Other outcomes of interest include acceptable outcomes (modified Rankin scale of 3 or less) and intracranial hemorrhage (ICH), and all-cause 90-day mortality. Outcomes for M1 patients were compared to M2 patients with multivariable logistic regression models accounting for potential confounders. Results 173 patients with M1 or M2 occlusions and low ASPECTS (<6) who underwent successful EVT were identified. After multivariable adjustments, M2 patients had significantly higher odds of futile reperfusion (OR 5.48 [95%CI 1.91 to 15.7], p = 0.002), lower odds of acceptable outcomes (OR 0.33 [95%CI 0.12 to 0.89], p = 0.028), and higher odds of all-cause mortality (OR 4.90 [95%CI 1.65 to 14.5], p = 0.004). These findings suggest that EVT's efficacy for low-ASPECTS stroke patients may be diminished for patients with M2 occlusions. M2 occlusion was not significantly associated with ICH. Conclusions Among low-ASEPCTS stroke patients who underwent successful EVT, those with M2 occlusions had significantly higher odds of poor outcome compared to those with M1 occlusions.
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index
Persano, Mara , Rimini, Margherita , Salani, Francesca , Prinzi, Federica Lo , Saborowski, Anna , Antonuzzo, Lorenzo , Passeri, Laura , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Corallo, Salvatore , Finkelmeier, Fabian , Pircher, Chiara , Braconi, Chiara , Qaisar, Aitzaz, Pirrone, Chiara, Castet, Florian , Parisi, Alessandro , Scartozzi, Mario, Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Rosa, Antonio De, Lanzetta, Irene, Balsano, Rita , Lavacchi, Daniele, Ikeda, Masafumi, Dekervel, Jeroen , Niger, Monica, Tesini, Giulia , Boccaccino, Alessandra , Himmelsbach, Vera, Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea, Vogel, Arndt , Casadei‐Gardini, Andrea , Kim, Jin Won , Abidoye, Oluseyi , Corallo, Salvatore , Rapposelli, Ilario Giovanni , Finkelmeier, Fabian , Pircher, Chiara , Pirrone, Chiara , Castet, Florian , Yoo, Changhoon , Oneda, Ester , Couto, Nuno , Adeva, Jorge , Tesini, Giulia , Djaballah, Selma Ahcene , Rimassa, Lorenza , Casadei-Gardini, Andrea , Antonuzzo, Lorenzo , Parisi, Alessandro , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Roque, Ricardo , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Vogel, Arndt , Rimini, Margherita , Nichetti, Federico , Vivaldi, Caterina , Lucchetti, Jessica , Kim, Jin Won , Tamberi, Stefano , Giordano, Guido , Chon, Hong Jae , Tamburini, Emiliano , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Verrico, Monica , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Farinea, Giovanni , Fornaro, Lorenzo , Camera, Silvia , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Bekaii‐Saab, Tanios , Esposito, Luca , Ferrara, Michele , Landriscina, Matteo , Masi, Gianluca , Lonardi, Sara

Mayo Clinic

Liver International | June 17, 2025 | Volume: 45 | Issue: 7 | Pages: No page available

10.1111/liv.70181 | PMID 40525496 Get It

ABSTRACT Background Over the years, prognostic indexes have been developed to help clinicians stratify patients with biliary tract cancers (BTC) into risk groups. This study aims to identify a new prognostic index for patients with BTC treated with cisplatin, gemcitabine and durvalumab (CGD) in the first‐line setting. Patients and Methods The study population consisted of patients with BTC from 11 Eastern and Western Countries. Using multivariate analysis for overall survival (OS), we identified 5 baseline statistically significant variables: stage, carcinoembryonic antigen (CEA) levels, albumin levels, gamma glutamyl transferase (GGT) levels, neutrophil‐to‐lymphocyte ratio (NLR). Metastatic disease is a prognostic factor with a superior weight considering the HR of 3.62, while all the others can be considered prognostic factors with equivalent weight as the HRs are quite similar (HRs between 1.55 and 1.92). Based on these reasons, we developed a prognostic model called the MAGIC‐D index by assigning a score of 2 for metastatic disease, and a score of 1 for CEA increased levels, albumin decreased levels, GGT increased levels, NLR ≥ 3. Patients were stratified into three risk groups as follows: low‐risk group (Score from 0 to 2), intermediate‐risk group (Score from 3 to 4) and high‐risk group (Score from 5 to 6). At the first data cutoff (April 2024), these data were available for 319 patients that composed the training cohort used for the analysis. At the second data cutoff (May 2025), 79 patients were further enrolled and composed the validation cohort. Results Median progression‐free survival was 11.7 months in low‐risk group (20.7%), 8.7 months in intermediate‐risk group (46.4%) and 5.4 months in high‐risk group (32.9%) [low‐risk hazard ratio (HR): 0.27, intermediate‐risk HR: 0.55, high‐risk HR: 1, p < 0.0001]. Median OS was 18.4 months in low‐risk group,15.9 months in intermediate‐risk group and 7.8 months in high‐risk group (low‐risk HR: 0.17, intermediate‐risk HR: 0.43, high‐risk HR: 1, p < 0.0001). There was no difference in overall response rate (low‐risk: 31.8%, intermediate‐risk: 36.5% and high‐risk: 25.7%; p = 0.0718), while disease control rate was significantly different across the three risk groups (low‐risk: 83.3%, intermediate‐risk: 70.9% and high‐risk: 60.9%; p < 0.0001) as well as the rate of patients receiving a second‐line therapy (low‐risk: 54.5%, intermediate‐risk: 48.6% and high‐risk: 25.7%; p = 0.0061). Finally, the prognostic role in terms of OS and PFS of the MAGIC‐D index was confirmed in a validation cohort of 79 patients. Conclusion The MAGIC‐D index is an easy‐to‐use tool able to stratify patients with BTC with different prognoses undergoing first‐line therapy with CGD.
Meningitis as an Attack Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
Aboseif, Albert , Kim, Nee Na , Bou, Gabriela , Nathoo, Nabeela , Guo, Yong , Pique, Julie , Kerbrat, Anne, Audoin, Bertrand, Demortière, Sarah , Bourre, Bertrand , Ciron, Jonathan , Chen, John J. , Tolédano, Michel B. , Quek, Amy May Lin, Marignier, Romain , Chen, John J , Ciron, Jonathan , Nathoo, Nabeela , Aboseif, Albert , Kerbrat, Anne , Audoin, Bertrand , Bourre, Bertrand , Cacciaguerra, Laura , Toledano, Michel, Gombolay, Grace , Hacohen, Yael , Flanagan, Eoin P.

Mayo Clinic

JAMA Neurology | June 16, 2025 | Volume: 82 | Issue: 8 | Pages: 871

10.1001/jamaneurol.2025.1774 | PMID 40522676 Get It

This international multicenter study seeks to determine the frequency and characteristics of meningitis in myelin oligodendrocyte glycoprotein antibody (MOGAD)–associated disease and highlight its pathology.
242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY
Cho, S. , Poon, Michelle, Bachy, E., Guidez, Stéphanie , Jagadeesh, Deepa , Mayer, L, Tani, M., Ambati, Srikanth, Uppala, Amulya , Brouwer‐Visser, Jurriaan , Chaudhry, A., Kim, T. M., Luminari, Stefano , Taszner, Michał , Chong, Geoffrey , Novelli, Silvana , Villasboas, José C. , Merli, Michele , Ubieto, Ana Jiménez , Tessoulin, Benoit , Tucker, David , Walewski, Jan , Yi, S., Song, Yuqin , Alonso, Aránzazu , Iskierka‐Jazdzewska, Elżbieta , Cai, James J. , Shariff, S., Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_242 Get It

Complex Single-Stage Juvenile Nasopharyngeal Angiofibroma Resection: A Hybrid Pediatric Endoscopic Endonasal and Transmaxillary Approach
Valencia, Bastien A. , Plata, Hector Fuentes, Kim, Jeeho D. , Levy, Danielle, Nation, Javan , Pannell, J. Scott, Patel, Vijay A. , Levy, Michael L. , Valencia‐Sanchez, Bastien A. , Patel, Vijay A , Plata, Hector, Brandel, Michael G. , Lévy, Michaël

Mayo Clinic

Operative Neurosurgery | June 16, 2025 | Volume: 30 | Issue: 5 | Pages: 740-744

10.1227/ons.0000000000001662 | PMID 40521907 Get It

BACKGROUND AND IMPORTANCE: Juvenile nasopharyngeal angiofibroma (JNA) is a rare, locally aggressive vascular tumor that primarily affect adolescent males. This work illustrates a step-by-step surgical approach of an advanced-stage JNA resection in a prepubescent 5-year-old child, utilizing a hybrid endoscopic endonasal and transmaxillary approach that provides highly effective results without employing traditional open techniques. CLINICAL PRESENTATION: A previously healthy 5-year-old male presented with one-year history of nasal obstruction, mouth breathing, and recurrent otitis media. The patient was found to have a large, space-occupying hypervascular tumor obstructing the nasopharynx. Preoperative radiographic imaging revealed an extensive heterogeneous, avidly enhancing mass that occupied the nasopharynx, right pterygopalatine fossa, infratemporal fossa, masticator space, and middle cranial fossa. Following superselective endovascular embolization, a hybrid endoscopic endonasal approach was planned for JNA resection, incorporating an anterior maxillotomy to allow for direct access to lateral compartments not classically amenable to conventional transnasal corridors. CONCLUSION: This study demonstrates the technical feasibility of a combined endoscopic endonasal and transmaxillary approach for single-stage JNA resection with intracranial extension in pediatric patients. Key principles include tumor embolization, dynamic endoscopic visualization, avoidance of brain retraction, direct access to critical neurovascular structures, and minimizing craniofacial morbidity.
441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
Cordoba, R., Perini, Guilherme Fleury , Jørgensen, Judit , Bijou, Fontanet , Munoz, J., Kim, W. S., Rao, P. , Moucheron, Bérengère de, Yang, Gang , Carrancio, Soraya , Sudhindra, Akshay, Voetsch, Jessica, Cordoba, R., Chavez, Julio C , Nastoupil, Loretta J. , Bories, Pierre , Zinzani, Pier Luigi , Munoz, J., Carpio, Cecilia del Carmen , Costa, Alfredo Cardoso , Pourdehnad, Michael , Michot, Jean‐Marie

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_441 Get It

Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma
Zhang, Weiwei , Sharma, Sunandini , Shah, Roshani , Lone, Waseem , Mehmood, Syed Karman, Chawla, Ravneet Singh, Cappelli, Luca Vincenzo , Heavican‐Foral, Tayla B. , Cannatella, Jeffrey J. , Amador, Catalina, Arif, Aiza, Lim, Soon Thye , Ong, Choon Kiat , Du, Ming‐Qing , Perry, Anamarija M. , Greiner, Timothy C. , Fu, Kai , Trøen, Gunhild, Weinstock, David M. , Laginestra, Antonella, Kim, KyeongJin , Vose, Julie, Weisenburger, Dennis D., Davé, Sandeep S. , Khoury, Joseph D. , Chan, Wing C., Iqbal, Javeed , Bouska, Alyssa , Lone, Waseem G , Cappelli, Luca Vincenzo , Ong, Choon Kiat , Weinstock, David M , Iqbal, Javeed , Holte, Harald , Shah, Rauf A., Soma, Mahfuza Afroz , Yang, Ruimeng , Liu, Xuxiang , Chawla, Ravneet Singh, Fiore, Danilo , Gong, Qiang , Heavican, Tayla B., Smith, Lynette M. , Feldman, Andrew L. , Leval, Laurence de , Vodák, Daniel , Nakken, Sigve , Delabie, Jan , Pileri, Stefano , Pajvani, Utpal B. , Weisenburger, Dennis D. , Horwitz, Steven M. , Inghirami, Giorgio

Mayo Clinic

American Journal of Hematology | June 13, 2025 | Volume: 100 | Issue: 9 | Pages: 1486-1501

10.1002/ajh.27736 | PMID 40510016 Get It

ABSTRACTNodal follicular helper T‐cell (T FH) lymphoma of the angioimmunoblastic (AITL) subtype has a dismal prognosis. Using whole‐exome sequencing (n = 124), transcriptomic (n = 78), and methylation (n = 40) analysis, we identified recurrent mutations in known epigenetic drivers (TET2, DNMT3A, IDH2 R172 ) and novel ones (TET3, KMT2D). TET2, IDH2 R172 , DNMT3A co‐mutated AITLs had poor prognosis (p < 0.0001). Genes regulating T‐cell receptor (TCR) signaling (CD28, PLCG1, VAV1, FYN) or activation (RHOA G17V ) or regulators of the PI3K‐pathway (PIK(3)C members, PTEN, PHLPP1, PHLPP2) were mutated. CD28 mutation/fusion was associated with poor prognosis (p = 0.02). WES of purified, neoplastic T‐cell (CD3+PD1+) demonstrated high concordance with whole tumor biopsies and validated the presence of TET2 and DNMT3A in tumor and non‐lymphoid cells, but other mutations (CD28, RHOA G17V , IDH2 R172 , PLCG1) in neoplastic cells. Integrated DNA‐methylation and mRNA expression analysis revealed epigenetic alterations in genes regulating TCR, cytokines, PI3K‐signaling, and apoptosis. RNA‐seq analysis identified fusion transcripts regulating TCR‐activation (8%), revealed a restricted TCR‐repertoire (α = 87%, β = 72%), and showed the presence of Epstein–Barr virus transcriptome (73%). GEP demonstrated the association of B‐cells or dendritic cells in the tumor milieu with prognosis (p < 0.01). RNA‐seq and WES analysis of 12 AITL‐patient‐derived‐xenografts (PDX) showed that bi‐allelic TET2 and DNMT3A mutations or sub‐clonal mutations (PLCG1, PHLPP2) propagated in sequential passages, and gene signatures related to T FH and T CM (central‐memory) were well‐maintained through passages. Gene expression signatures associated with late PDX passages (3rd–5th) were enriched with proliferation and metabolic reprogramming‐related genes and predicted prognosis in an independent AITL series. Low PHLPP2 mRNA expression predicted poor prognosis (p = 0.05) and engineered PHLPP2 or TET2 loss in CD4+ T‐cells showed enhanced PI(3)K activation, thus uncovering a therapeutic target for clinical trials.